New drug may reduce blood transfusions for anemia patients
NCT ID NCT06847867
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called momelotinib in 80 adults with low-risk myelodysplastic syndromes who have anemia. The goal is to see if it can help them need fewer red blood cell transfusions. Participants will receive different doses to find the safest and most effective one.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
RECRUITINGGoodyear, Arizona, 85338, United States
-
GSK Investigational Site
RECRUITINGDuarte, California, 91010-3012, United States
-
GSK Investigational Site
RECRUITINGIrvine, California, 92618, United States
-
GSK Investigational Site
RECRUITINGNew Haven, Connecticut, 06519-1110, United States
-
GSK Investigational Site
RECRUITINGCanton, Ohio, 44718, United States
-
GSK Investigational Site
RECRUITINGHouston, Texas, 77030, United States
-
GSK Investigational Site
RECRUITINGCalgary, Alberta, T2N 5G2, Canada
-
GSK Investigational Site
RECRUITINGToronto, Ontario, M5G 2M9, Canada
-
GSK Investigational Site
RECRUITINGLe Mans, 72015, France
-
GSK Investigational Site
RECRUITINGNice, 06202, France
-
GSK Investigational Site
RECRUITINGParis, 75010, France
-
GSK Investigational Site
RECRUITINGPoitiers, 86021, France
-
GSK Investigational Site
RECRUITINGToulouse, 31059, France
-
GSK Investigational Site
RECRUITINGMünster, North Rhine-Westphalia, 48149, Germany
-
GSK Investigational Site
RECRUITINGDresden, 01307, Germany
-
GSK Investigational Site
RECRUITINGLeipzig, 04103, Germany
-
GSK Investigational Site
RECRUITINGUdine, Friuli Venezia Giulia, 33100, Italy
-
GSK Investigational Site
RECRUITINGCatania, 95123, Italy
-
GSK Investigational Site
RECRUITINGFlorence, 50134, Italy
-
GSK Investigational Site
RECRUITINGMilan, 20122, Italy
-
GSK Investigational Site
RECRUITINGOrbassano to, 10043, Italy
-
GSK Investigational Site
RECRUITINGRozzano MI, 20089, Italy
-
GSK Investigational Site
RECRUITINGChorzów, Silesian Voivodeship, 40-523, Poland
-
GSK Investigational Site
RECRUITINGWarsaw, 02-172, Poland
-
GSK Investigational Site
RECRUITINGSeongnam-si Gyeonggi-do, 13620, South Korea
-
GSK Investigational Site
RECRUITINGSeoul, 03080, South Korea
-
GSK Investigational Site
RECRUITINGSeoul, 05505, South Korea
-
GSK Investigational Site
RECRUITINGSeoul, 06591, South Korea
-
GSK Investigational Site
RECRUITINGBarcelona, 8035, Spain
-
GSK Investigational Site
RECRUITINGBarcelona, 8907, Spain
-
GSK Investigational Site
RECRUITINGMadrid, 28027, Spain
-
GSK Investigational Site
RECRUITINGMálaga, 29010, Spain
-
GSK Investigational Site
RECRUITINGOurense, 32005, Spain
-
GSK Investigational Site
RECRUITINGPamplonaNavarra, 31008, Spain
-
GSK Investigational Site
RECRUITINGSalamanca, 37007, Spain
-
GSK Investigational Site
RECRUITINGValencia, 46010, Spain
-
GSK Investigational Site
RECRUITINGBoston, PE21 9QS, United Kingdom
-
GSK Investigational Site
RECRUITINGLondon, SE5 9RS, United Kingdom
-
GSK Investigational Site
RECRUITINGManchester, M20 4BX, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- Can engineered immune cells outsmart Hard-to-Treat blood cancers?
- Can a new drug offer hope for blood cancers when chemo fails?
- Can a Gene-Targeted pill turn the tide against a rare blood cancer?